9 completed, 5 recruiting, 4 terminated, 2 unknown. 11 Phase 2, 9 Phase 1, 6 Phase 3, 1 Not applicable, 1 Phase 4.
Follow Netherton Syndrome: new trials by email Literature Review of Netherton Syndrome trials Research Report on Netherton Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Skin and Gut Microbiome in a Skin Condition Involving Skin Barrier Impairment and Allergic Symptoms: Netherton Syndrome Superficial skin swabs, Stool samples, Saliva samples - Netherton Syndrome | Recruiting | Assistance Publique - Hôpitaux de Paris | 30 | 2026-05-26 | 2026-06-30 | |
| Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome QRX003 - Netherton Syndrome | Phase 2 / Phase 3 | Recruiting | Quoin Pharmaceuticals | 16 | 2026-03-19 | 2026-09-28 |
| Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome QRX003, 4% Lotion - Netherton Syndrome | Phase 2 / Phase 3 | Recruiting | Quoin Pharmaceuticals | 8 | 2025-10-06 | 2026-08-31 |
| Natural History of Netherton Syndrome Netherton Syndrome | Terminated | Boehringer Ingelheim | 4 | 2024-10-09 | 2026-06-24 | |
| A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725 BCX17725, Placebo - Netherton Syndrome | Phase 1 | Recruiting | BioCryst Pharmaceuticals | 78 | 2024-09-26 | 2026-08-27 |
| Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome ATR12-351 - Netherton Syndrome | Phase 1 | Completed | Azitra Inc. | 6 | 2024-06-16 | 2026-07-29 |
| A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome DS-2325a, Placebo - Netherton Syndrome | Phase 1 / Phase 2 | Terminated | Daiichi Sankyo | 9 | 2023-09-28 | 2026-05-14 |
| A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome Spesolimab - solution for infusion, Placebo matching to spesolimab - solution for infusion, Spesolimab - solution for injection - Netherton Syndrome | Phase 2 / Phase 3 | Terminated | Boehringer Ingelheim | 43 | 2023-06-12 | 2026-03-12 |
| Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome QRX003, 4% Lotion - Netherton Syndrome | Phase 2 / Phase 3 | Recruiting | Quoin Pharmaceuticals | 20 | 2023-03-14 | 2026-08-31 |
| A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects DS-2325a, Placebo - Netherton Syndrome | Phase 1 | Completed | Daiichi Sankyo | 24 | 2022-11-08 | 2023-05-18 |
| Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome QRX003-2% Lotion, QRX003-4% Lotion QAM, Vehicle - Netherton Syndrome | Phase 2 / Phase 3 | Active not recruiting | Quoin Pharmaceuticals | 30 | 2022-06-23 | 2026-03-16 |
| A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects DS-2325a, Placebo - Netherton Syndrome | Phase 1 | Completed | Daiichi Sankyo | 64 | 2022-06-20 | 2023-03-06 |
| A Study to Evaluate Topically Applied SXR1096 Cream in Patients With Netherton Syndrome SXR1096 cream, Placebo cream - Netherton Syndrome | Phase 1 / Phase 2 | Completed | Sixera Pharma | 9 | 2021-12-07 | 2025-12-16 |
| Scientific Substantiation and Assessment of the Effectiveness of Pathogenetic Methods of Therapy for Congenital Ichthyosis in Children Secukinumab Injection, Ustekinumab Injection, Dupilumab Injection - Congenital Ichthyosis | Phase 4 | Unknown | National Medical Research Center for Children's Health, Russian Federation | 50 | 2021-03-01 | 2021-08-09 |
| A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome Dupilumab Prefilled Syringe, Placebo Prefilled Syringe - Netherton Syndrome | Phase 2 / Phase 3 | Terminated | University Hospital, Toulouse | 10 | 2020-07-23 | 2026-09-21 |
| Defining the Skin and Blood Biomarkers of Ichthyosis Ichthyosis, Netherton Syndrome | Enrolling by invitation | Northwestern University | 200 | 2018-01-31 | 2026-04-27 | |
| The Efficacy and Safety of Secukinumab in Patients With Ichthyoses Secukinumab, Placebo - Ichthyosis, Autosomal Recessive Congenital Ichthyosis | Phase 2 | Completed | Northwestern University | 20 | 2016-12-01 | 2021-08-25 |
| Natural History and Biological Study of Netherton Syndrome Biopsy, Blood sample - Netherton Syndrome, Healthy | Not applicable | Completed | Institut National de la Santé Et de la Recherche Médicale, France | 18 | 2014-10-01 | 2025-12-04 |
| Gene Therapy for Netherton Syndrome One 20cm2/10cm2 autologous skin sheet graft - Netherton Syndrome | Phase 1 | Unknown | Great Ormond Street Hospital for Children NHS Foundation Trust | 5 | 2014-04-01 | 2016-10-19 |
| Clinical Trial Using Humira in Netherton Syndrome Adalimumab - Netherton Syndrome | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 11 | 2014-01-27 | 2026-04-08 |
Showing 20 of 22. Sign in to see all of them.
Ichthyosis (3) · Dermatitis, Atopic (1) · Eczema (1) · Hyperkeratosis, Epidermolytic (1) · Ichthyosiform Erythroderma, Congenital (1) · Ichthyosis Vulgaris (1) · Ichthyosis, Lamellar (1) · Skin Diseases (1) · Skin Diseases, Eczematous (1) · Skin Diseases, Genetic (1)
Abnormalities, Multiple (22) · Congenital Abnormalities (22) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (22) · Genetic Diseases, Inborn (22) · Infant, Newborn, Diseases (22) · Keratosis (22) · Skin Abnormalities (22) · Skin and Connective Tissue Diseases (22) · Ichthyosiform Erythroderma, Congenital (21) · Skin Diseases (21) · Skin Diseases, Genetic (21) · Ichthyosis (19) · Dermatitis (1) · Hypersensitivity (1) · Hypersensitivity, Immediate (1)
Blood Specimen Collection (2) · secukinumab (2) · Adalimumab (1) · Biopsy (1) · Data Collection (1) · Injections (1) · Ustekinumab (1) · WAS protein, human (1) · dupilumab (1) · pimecrolimus (1) · spesolimab (1)
Quoin Pharmaceuticals (4) · Daiichi Sankyo (3) · Assistance Publique - Hôpitaux de Paris (2) · Boehringer Ingelheim (2) · Northwestern University (2) · Azitra Inc. (1) · BioCryst Pharmaceuticals (1) · Children's Hospital of Philadelphia (1) · Great Ormond Street Hospital for Children NHS Foundation Trust (1) · Institut National de la Santé Et de la Recherche Médicale, France (1) · National Medical Research Center for Children's Health, Russian Federation (1) · Novartis Pharmaceuticals (1) · Sixera Pharma (1) · University Hospital, Toulouse (1)
United States (14) · France (8) · Germany (3) · Netherlands (3) · United Kingdom (3) · Australia (2) · Italy (2) · Austria (1) · Bulgaria (1) · China (1) · Israel (1) · Japan (1) · Malaysia (1) · Portugal (1) · Russia (1)
Tony Andrasfay (2) · Alain Hovnanian, MD, PhD (1) · Albert C Yan, MD (1) · Amy Paller, MD (1) · Christine Bodemer, MD, PhD (1) · Emma Guttman-Yassky, MD, PhD (1) · Jemima Mellerio, Dr (1) · Maarten de Chateau, MD PhD (1) · Mary Spellman, MD (1)
PMID 20083693, PMID 24329107, PMID 34543653, PMID 35218370, PMID 40908106
2014 (1), 2025 (1)